Related Experiment Video

Updated: Sep 24, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.0K

PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer

Ronan Flippot1, Anna Patrikidou1, Mihaela Aldea1

  • 1Department of Cancer Medicine, Paris Saclay University, Gustave Roussy, 114 rue Edouard Vaillant, 94 800, Villejuif, France.

Drugs
|May 5, 2022
PubMed

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors show promise for treating metastatic castrate-resistant prostate cancer (mCRPC), especially in patients with BRCA1/2 mutations. Further research is needed to optimize their use and overcome challenges.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • 25% of metastatic prostate cancer patients have DNA damage repair alterations, linked to aggressive disease.
  • Poly(ADP-ribose) polymerase (PARP) inhibitors are emerging as a key treatment strategy for metastatic castrate-resistant prostate cancer (mCRPC).

Purpose of the Study:

  • To review the rationale for PARP inhibition in prostate cancer.
  • To discuss the impact of PARP inhibitors on patient outcomes.
  • To explore challenges and future directions for PARP inhibitor development in prostate cancer.

Main Methods:

  • Review of clinical trial data for PARP inhibitors (olaparib, rucaparib, talazoparib, niraparib) in mCRPC.
  • Analysis of patient cohorts with specific DNA damage repair gene mutations (BRCA1, BRCA2, ATM).
  • Examination of ongoing combination therapy trials with PARP inhibitors.

Main Results:

  • Olaparib demonstrated improved survival in patients with BRCA1, BRCA2, or ATM mutations in the PROfound trial.
  • Other PARP inhibitors show compelling activity in phase II trials for mCRPC.
  • Benefit from PARP inhibition appears greatest for BRCA1/2 mutations, with lesser benefit for other homologous recombination gene mutations.

Conclusions:

  • PARP inhibitors represent a significant advancement in mCRPC treatment, particularly for patients with BRCA mutations.
  • Combination therapies involving PARP inhibitors are under investigation across various disease stages.
  • Further research is essential to optimize PARP inhibitor efficacy and address challenges in their clinical application.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

628

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
264
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
258
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
267